CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to COGT

Bezuclastinib in combination with sunitinib

Phase 2
Cogent Biosciences, Inc. (COGT)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
2mo
COGTPDUFA
Phase 2

FDA PDUFA Date Bezuclastinib

Bezuclastinib in combination with sunitinib
Nov 30
Source
00%
Competitive Landscape

0 competitors in Gastrointestinal Stromal Tumors

View Full Landscape
Drug Information

Target Indication

Gastrointestinal Stromal Tumors

Clinical Trial

NCT06208748

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.